H Marotte1, E Gineyts, P Miossec, P D Delmas. 1. Hospices Civils de Lyon-bioMérieux Research Unit on Rheumatoid Arthritis, Hospital Edouard Herriot, Lyon, France. hubert.marotte@laposte.net
Abstract
BACKGROUND: Defining the remission criteria of rheumatoid arthritis (RA) remains a critical issue. Markers of synovium activity, urinary glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) and of cartilage destruction, urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II) have been shown to reflect disease activity and joint damage progression in RA. METHODS: The prospective study cohort comprised 66 RA patients treated with infliximab and methotrexate and 76 healthy controls. Measurements of urinary Glc-Gal-PYD and CTX-II were performed at baseline and at 1 year of infliximab therapy. RESULTS: At baseline, urinary Glc-Gal-PYD and CTX-II levels were increased in patients with RA and correlated with modified Sharp scores and progression of joint damage. Patients with more progressive joint destruction had higher Glc-Gly-PYD and CTX-II baseline levels. CONCLUSION: These markers reflected bone erosion evolution and might be useful for treatment monitoring and evaluation of RA. Markers remained high even in clinical responders after infliximab, suggesting persistence of synovitis.
BACKGROUND: Defining the remission criteria of rheumatoid arthritis (RA) remains a critical issue. Markers of synovium activity, urinary glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) and of cartilage destruction, urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II) have been shown to reflect disease activity and joint damage progression in RA. METHODS: The prospective study cohort comprised 66 RApatients treated with infliximab and methotrexate and 76 healthy controls. Measurements of urinary Glc-Gal-PYD and CTX-II were performed at baseline and at 1 year of infliximab therapy. RESULTS: At baseline, urinary Glc-Gal-PYD and CTX-II levels were increased in patients with RA and correlated with modified Sharp scores and progression of joint damage. Patients with more progressive joint destruction had higher Glc-Gly-PYD and CTX-II baseline levels. CONCLUSION: These markers reflected bone erosion evolution and might be useful for treatment monitoring and evaluation of RA. Markers remained high even in clinical responders after infliximab, suggesting persistence of synovitis.
Authors: Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen Journal: Arthritis Res Ther Date: 2011-04-28 Impact factor: 5.156
Authors: Marije F Bakker; Suzanne M M Verstappen; Paco M J Welsing; Johannes W G Jacobs; Zalima N Jahangier; Maaike J van der Veen; Johannes W J Bijlsma; Floris P J G Lafeber Journal: Arthritis Res Ther Date: 2011-05-08 Impact factor: 5.156
Authors: Ravi C Dwivedi; Navjot Dhindsa; Oleg V Krokhin; John Cortens; John A Wilkins; Hani S El-Gabalawy Journal: Arthritis Res Ther Date: 2009-03-06 Impact factor: 5.156
Authors: Giovanni Lombardi; Patrizia Lanteri; Pier Luigi Fiorella; Luigi Simonetto; Franco M Impellizzeri; Marco Bonifazi; Giuseppe Banfi; Massimo Locatelli Journal: PLoS One Date: 2013-04-30 Impact factor: 3.240